Clinical Trial

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
RP2-001-18 is a Phase 1, multicenter, open label, single agent dose escalation and combination treatment study of RP2 in adult subjects with advanced solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Protocol Amendment History 1 change
notable Sponsor changed: Replimune Inc. -> Replimune, Inc. 2026-04-19
Trial Details
NCT Number NCT04336241
Lead Sponsor Replimune Inc.
Conditions Cancer
Enrollment 36 participants
Start Date 2019-10-17
Primary Completion 2026-10-31 (estimated)
Study Completion 2026-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-27